• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    ACADIA Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    5/7/25 4:13:19 PM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACAD alert in real time by email
    8-K
    0001070494false00010704942025-05-072025-05-07

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): May 07, 2025

     

     

    Acadia Pharmaceuticals Inc.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    000-50768

    06-1376651

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    12830 El Camino Real, Suite 400

     

    San Diego, California

     

    92130

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: (858) 558-2871

     

    N/A

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common Stock, par value $0.0001 per share

     

    ACAD

     

    The Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


    Item 2.02 Results of Operations and Financial Condition.

    On May 7, 2025, Acadia Pharmaceuticals Inc. issued a press release announcing its financial results for the three months ended March 31, 2025. A copy of this press release is furnished herewith as Exhibit 99.1. Pursuant to the rules and regulations of the Securities and Exchange Commission, such exhibit and the information set forth therein and in this Item 2.02 have been furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to liability under that section nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing regardless of any general incorporation language.

    Item 9.01 Financial Statements and Exhibits.

    (d) Exhibits.

    Exhibit
    Number

    Description

    99.1

    Press Release dated May 7, 2025.

    104

    Cover page Interactive Data File (embedded within the Inline XBRL document).

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

     

     

     

    Acadia Pharmaceuticals Inc.

     

     

     

     

    Date:

    May 7, 2025

    By:

    /s/ Jennifer J. Rhodes

     

     

     

    Jennifer J. Rhodes
    Executive Vice President, Chief Legal Officer & Secretary

     


    Get the next $ACAD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ACAD

    DatePrice TargetRatingAnalyst
    2/11/2025$22.00Hold
    Deutsche Bank
    1/3/2025$23.00 → $20.00Buy → Neutral
    Guggenheim
    10/10/2024Mkt Perform
    Raymond James
    8/7/2024$28.00 → $20.00Overweight → Equal-Weight
    Morgan Stanley
    6/27/2024$31.00Outperform
    BMO Capital Markets
    3/12/2024$36.00 → $32.00Buy
    Needham
    3/12/2024$39.00 → $25.00Buy → Neutral
    Mizuho
    1/30/2024$40.00Outperform
    Robert W. Baird
    More analyst ratings

    $ACAD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Acadia Pharmaceuticals Reports First Quarter 2025 Financial Results and Operating Overview

      - First quarter total revenues of $244.3 million, up 19% year-over-year - First quarter NUPLAZID® (pimavanserin) net product sales of $159.7 million, up 23% year-over-year - First quarter DAYBUE® (trofinetide) net product sales of $84.6 million, up 11% year-over-year, and up 9.5% in unique patients shipped - Reiterates full year 2025 revenue guidance including DAYBUE net sales of $380 to $405 million and NUPLAZID net sales of $650 to $690 million - Accelerated timing for COMPASS PWS Phase 3 study of ACP-101 in Prader Willi Syndrome, topline results now expected in early Q4 2025 Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced its financial results for the first quarter ended M

      5/7/25 4:05:00 PM ET
      $ACAD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Acadia Pharmaceuticals to Participate in the BofA Securities 2025 Health Care Conference

      Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that it will participate in a fireside chat at the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025 at 3:40 p.m. Pacific Time. A live webcast of Acadia's fireside chat will be accessible on the company's website, Acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following the presentation. About Acadia Pharmaceuticals Acadia is advancing breakthroughs in neuroscience to elevate life. Since our founding we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commerciali

      5/5/25 4:05:00 PM ET
      $ACAD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 7, 2025

      Company to host conference call and webcast on Wednesday, May 7, 2025, at 4:30 p.m. Eastern Time Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that it will report first quarter financial results on Wednesday, May 7, 2025, after the close of the U.S. financial markets. Acadia's management team will also host a conference call and webcast on May 7, 2025, at 4:30 p.m. Eastern Time. The webcast will be available on Acadia's website, Acadia.com under the investors section and will be archived there until August 6, 2025. The conference call may also be accessed by registering for the call here. Once registered, participants will receive an email with the dial-in number and unique PI

      4/23/25 4:05:00 PM ET
      $ACAD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACAD
    SEC Filings

    See more
    • SEC Form S-3 filed by ACADIA Pharmaceuticals Inc.

      S-3 - ACADIA PHARMACEUTICALS INC (0001070494) (Filer)

      5/9/25 4:06:41 PM ET
      $ACAD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by ACADIA Pharmaceuticals Inc.

      10-Q - ACADIA PHARMACEUTICALS INC (0001070494) (Filer)

      5/7/25 9:15:42 PM ET
      $ACAD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ACADIA Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - ACADIA PHARMACEUTICALS INC (0001070494) (Filer)

      5/7/25 4:13:19 PM ET
      $ACAD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACAD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Deutsche Bank initiated coverage on ACADIA Pharmaceuticals with a new price target

      Deutsche Bank initiated coverage of ACADIA Pharmaceuticals with a rating of Hold and set a new price target of $22.00

      2/11/25 7:00:07 AM ET
      $ACAD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ACADIA Pharmaceuticals downgraded by Guggenheim with a new price target

      Guggenheim downgraded ACADIA Pharmaceuticals from Buy to Neutral and set a new price target of $20.00 from $23.00 previously

      1/3/25 7:17:06 AM ET
      $ACAD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Raymond James resumed coverage on ACADIA Pharmaceuticals

      Raymond James resumed coverage of ACADIA Pharmaceuticals with a rating of Mkt Perform

      10/10/24 8:39:02 AM ET
      $ACAD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACAD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by ACADIA Pharmaceuticals Inc.

      SC 13G/A - ACADIA PHARMACEUTICALS INC (0001070494) (Subject)

      11/14/24 6:48:52 AM ET
      $ACAD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by ACADIA Pharmaceuticals Inc.

      SC 13G - ACADIA PHARMACEUTICALS INC (0001070494) (Subject)

      2/14/24 7:08:13 AM ET
      $ACAD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by ACADIA Pharmaceuticals Inc. (Amendment)

      SC 13G/A - ACADIA PHARMACEUTICALS INC (0001070494) (Subject)

      2/13/24 4:56:01 PM ET
      $ACAD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACAD
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for NUPLAZID issued to ACADIA PHARMS INC

      Submission status for ACADIA PHARMS INC's drug NUPLAZID (SUPPL-9) with active ingredient PIMAVANSERIN TARTRATE has changed to 'Approval' on 09/15/2023. Application Category: NDA, Application Number: 210793, Application Classification: Efficacy

      9/18/23 10:47:05 AM ET
      $ACAD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for NUPLAZID issued to ACADIA PHARMS INC

      Submission status for ACADIA PHARMS INC's drug NUPLAZID (SUPPL-12) with active ingredient PIMAVANSERIN TARTRATE has changed to 'Approval' on 09/15/2023. Application Category: NDA, Application Number: 207318, Application Classification: Efficacy

      9/18/23 10:40:05 AM ET
      $ACAD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for DAYBUE issued to ACADIA PHARMS INC

      Submission status for ACADIA PHARMS INC's drug DAYBUE (ORIG-1) with active ingredient TROFINETIDE has changed to 'Approval' on 03/10/2023. Application Category: NDA, Application Number: 217026, Application Classification: Type 1 - New Molecular Entity

      3/13/23 10:37:07 AM ET
      $ACAD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACAD
    Leadership Updates

    Live Leadership Updates

    See more
    • Acadia Pharmaceuticals Set to Join S&P SmallCap 600

      NEW YORK, Dec. 30, 2024 /PRNewswire/ -- Acadia Pharmaceuticals Inc. (NASD: ACAD) will replace Independent Bank Group Inc. (NASD: IBTX) in the S&P SmallCap 600 effective prior to the opening of trading on Friday, January 3, 2025. S&P MidCap 400 constituent SouthState Corp. (NYSE:SSB) is acquiring Independent Bank Group in a deal expected to close soon pending final conditions. Following is a summary of the change that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector Jan 3, 2025 S&P SmallCap 600 Addition Acadia Pharmaceuticals ACAD Health Care Jan 3, 2025 S&P SmallCap 600 Deletion Independent Bank Group

      12/30/24 5:37:00 PM ET
      $ACAD
      $IBTX
      $SPGI
      $SSB
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Banks
      Finance
    • Acadia Pharmaceuticals Appoints Thomas Garner Chief Commercial Officer

      – Seasoned commercial executive with more than 25 years pharmaceutical and biotech experience Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that Thomas Andrew Garner has been appointed Chief Commercial Officer, effective today. Mr. Garner will spearhead Acadia's commercial strategy and operations, driving the Company's plans for sustained growth and expansion of its product portfolio and pipeline across U.S. and international markets. Mr. Garner will report to Catherine Owen Adams, Acadia's CEO, and serve on the executive leadership team. "Tom is an accomplished commercial executive with a demonstrated history of driving brand growth across a wide range of therapeutic areas

      12/9/24 9:00:00 AM ET
      $ACAD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Catherine Owen Adams Succeeds Steve Davis as CEO of Acadia Pharmaceuticals

      - Ms. Owen Adams brings over 25 years of pharmaceutical industry experience including senior commercial leadership roles with Bristol Myers Squibb and Johnson & Johnson Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that Catherine Owen Adams has succeeded Steve Davis as Chief Executive Officer (CEO) and joined the Acadia Board of Directors. "We are excited to welcome Catherine Owen Adams as the new CEO of Acadia," said Stephen Biggar, M.D., Ph.D., Chair of the Board of Directors. "Catherine is a proven global leader with a distinguished record of accomplishment of driving growth and innovation in the pharmaceutical industry. Her strategic vision, deep expertise, and unwavering

      9/23/24 4:15:00 PM ET
      $ACAD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACAD
    Financials

    Live finance-specific insights

    See more
    • Acadia Pharmaceuticals Reports First Quarter 2025 Financial Results and Operating Overview

      - First quarter total revenues of $244.3 million, up 19% year-over-year - First quarter NUPLAZID® (pimavanserin) net product sales of $159.7 million, up 23% year-over-year - First quarter DAYBUE® (trofinetide) net product sales of $84.6 million, up 11% year-over-year, and up 9.5% in unique patients shipped - Reiterates full year 2025 revenue guidance including DAYBUE net sales of $380 to $405 million and NUPLAZID net sales of $650 to $690 million - Accelerated timing for COMPASS PWS Phase 3 study of ACP-101 in Prader Willi Syndrome, topline results now expected in early Q4 2025 Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced its financial results for the first quarter ended M

      5/7/25 4:05:00 PM ET
      $ACAD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 7, 2025

      Company to host conference call and webcast on Wednesday, May 7, 2025, at 4:30 p.m. Eastern Time Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that it will report first quarter financial results on Wednesday, May 7, 2025, after the close of the U.S. financial markets. Acadia's management team will also host a conference call and webcast on May 7, 2025, at 4:30 p.m. Eastern Time. The webcast will be available on Acadia's website, Acadia.com under the investors section and will be archived there until August 6, 2025. The conference call may also be accessed by registering for the call here. Once registered, participants will receive an email with the dial-in number and unique PI

      4/23/25 4:05:00 PM ET
      $ACAD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview

      - 2024 total net product sales of $957.8 million, reflecting 32% revenue growth - Fourth quarter DAYBUE® (trofinetide) net product sales of $96.7 million and full year 2024 net product sales of $348.4 million - Fourth quarter NUPLAZID® (pimavanserin) net product sales of $162.9 million and full year 2024 net product sales of $609.4 million - Full year 2025 total revenue guidance of $1.03 to $1.095 billion including DAYBUE net sales guidance of $380 to $405 million and NUPLAZID net sales guidance of $650 to $690 million Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced its financial results for the fourth quarter and full year ended December 31, 2024. "We closed 2024 on a s

      2/26/25 4:05:00 PM ET
      $ACAD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACAD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • PRINCIPAL ACCOUNTING OFFICER Kihara James converted options into 2,596 shares and sold $19,374 worth of shares (1,327 units at $14.60), increasing direct ownership by 6% to 23,526 units (SEC Form 4)

      4 - ACADIA PHARMACEUTICALS INC (0001070494) (Issuer)

      5/2/25 8:00:34 PM ET
      $ACAD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP, CHIEF FINANCIAL OFFICER Schneyer Mark C. converted options into 6,815 shares and sold $51,071 worth of shares (3,498 units at $14.60), increasing direct ownership by 6% to 62,773 units (SEC Form 4)

      4 - ACADIA PHARMACEUTICALS INC (0001070494) (Issuer)

      5/2/25 7:59:08 PM ET
      $ACAD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP, CHIEF FINANCIAL OFFICER Schneyer Mark C. converted options into 5,275 shares and sold $40,133 worth of shares (2,708 units at $14.82), increasing direct ownership by 5% to 59,456 units (SEC Form 4)

      4 - ACADIA PHARMACEUTICALS INC (0001070494) (Issuer)

      4/8/25 7:40:13 PM ET
      $ACAD
      Biotechnology: Pharmaceutical Preparations
      Health Care